<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Transplantation</journal-id><journal-id journal-id-type="iso-abbrev">Transplantation</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Transplantation</journal-title></journal-title-group><issn pub-type="ppub">0041-1337</issn><issn pub-type="epub">1534-6080</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10214926</article-id><article-id pub-id-type="pmcid-ver">PMC10214926.1</article-id><article-id pub-id-type="pmcaid">10214926</article-id><article-id pub-id-type="pmcaiid">10214926</article-id><article-id pub-id-type="manuscript-id">NIHMS1893677</article-id><article-id pub-id-type="pmid">35349533</article-id><article-id pub-id-type="doi">10.1097/TP.0000000000004049</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1893677</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1893677</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Rising Trend in Waitlisting for Alcoholic Hepatitis With More Favorable Outcomes Than Other High Model for End-stage Liver Disease in the Current Era</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bittermann</surname><given-names initials="T">Therese</given-names></name><degrees>MD, MSCE</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mahmud</surname><given-names initials="N">Nadim</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinberg</surname><given-names initials="EM">Ethan M.</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reddy</surname><given-names initials="KR">K. Rajender</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</aff><aff id="A2"><label>2</label>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.</aff><author-notes><corresp id="CR1">Correspondence: Therese Bittermann, MD, MSCE, Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104. (<email>therese.bittermann@pennmedicine.upenn.edu</email>).</corresp><fn fn-type="COI-statement" id="FN4"><p id="P39">The authors declare no conflicts of interest.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>24</day><month>3</month><year>2022</year></pub-date><volume>106</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">436669</issue-id><fpage>1401</fpage><lpage>1410</lpage><pub-history><event event-type="nihms-submitted"><date><day>17</day><month>05</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 12:25:14.010"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1893677.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background.</title><p id="P1">In the appropriate candidate, liver transplantation (LT) is a viable treatment for alcoholic hepatitis (AH). We compared the waitlisting trends and outcomes of AH patients in the context of others with high Model for End-stage Liver Disease (MELD) score.</p></sec><sec id="S2"><title>Methods.</title><p id="P2">LT listings for AH between January 1, 2008, and June 12, 2020 were identified in the United Network for Organ Sharing database. Temporal trends in listings for AH were assessed. Covariate adjusted competing risks models evaluated waitlist mortality and LT rates between AH candidates and others with listing native MELD &#8805;30.</p></sec><sec id="S3"><title>Results.</title><p id="P3">Between 2008 and 2019, waitlist additions for AH increased 6.5-fold. Waiting time for AH candidates was short (median 10 d). Delisting for clinical improvement was infrequent in AH, albeit higher than MELD &#8805;30 patients (3.3% versus 0.8%; <italic toggle="yes">P</italic> &lt; 0.001). Among 99 centers with &#8805;1 AH listing, AH patients accounted for 0.2%&#8211;18.2% of all alcohol-related listings and 0.6%&#8211;25.0% of those with native listing MELD &#8805;30. Overall listing volume was larger at these 99 centers than the 40 with no AH listings (<italic toggle="yes">P</italic> &lt; 0.001). AH candidates in 2014&#8211;2020 experienced improved waitlist survival (adjusted subhazard ratio, 0.67; 95% confidence interval, 0.52&#8211;0.86; <italic toggle="yes">P</italic> = 0.002) and higher transplant rates (adjusted subhazard ratio, 1.14; 95% confidence interval, 1.04&#8211;1.25; <italic toggle="yes">P</italic> = 0.006) versus other MELD &#8805;30 candidates.</p></sec><sec id="S4"><title>Conclusions.</title><p id="P4">There has been a rising trend in waitlisting patients with AH and high MELD score. Liver disease causes influence waitlist outcomes and those of AH candidates are more favorable. Further research and allocation adjustments may be needed to ensure equitable organ allocation, based on liver disease cause, for those on the LT waitlist.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>